Loading…
Loading…
IBBJ (Defiance Nasdaq Junior Biotechnology ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See exactly how IBBJ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IBBJ and 80,000+ other tickers.
This investment vehicle's primary objective is to track the overall performance, measured by total return, of the NASDAQ Junior Biotechnology Index, before accounting for any associated fees or expenses. The index itself is a rule-based compilation of U.S.-listed small-capitalization ("junior") biotechnology companies, carefully selected from the broader spectrum of businesses found within the NASDAQ Biotechnology Index. The fund typically implements a "replication" investment strategy, which means it generally acquires positions in all the component securities of its benchmark index, aiming to maintain their proportional weightings. This fund is designated as non-diversified.
Plus, a large number of name and index changes occurred during the past two weeks.
Plus, expense ratio changes and other ETF developments occurred during the week.
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that offers protection against both the coronavirus and the seasonal flu. The new vaccine booster, which the biotech company calls mRNA-1073, combines Moderna's current coronavirus vaccine [.
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could be the ETF to watch.